Robyn Mellett

Follow

Generating author description...

All published works

Action	Title	Year	Authors
+	Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug Development	2024	Hannah Moyer Robyn Mellett Karine Vigneault Maya McKeown Jason Karlawish Erika F. Augustine Lon S. Schneider Jonathan Kimmelman

Common Coauthors

Coauthor	Papers Together
Jason Karlawish	1
Jonathan Kimmelman	1
Hannah Moyer	1
Lon S. Schneider	1
Erika F. Augustine	1
Karine Vigneault	1
Maya McKeown	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Power Calculations for Clinical Trials in Alzheimer's Disease	2011	M. Colin Ard Steven D. Edland	1
+	Improving Alzheimer's disease phase II clinical trials	2012	Barry Greenberg María C. Carrillo J. Michael Ryan Michael Gold Kim P. Gallagher Michael Grundman Robert Berman T. Ashwood Eric Siemers	1
+	Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials	2023	Hannah Moyer Merlin Bittlinger Angela Nelson Luciano Fernandez Jacky Sheng Yuetong Wang Joseph C. Del Paggio Jonathan Kimmelman	1